ER+/PR+, HER2-breast cancer treated with allosteric mTOR inhibitor, everolimus, which together with Anastrozole, an aromatase inhibitor, has shown improved overall response rates (Baselga et al., 2014). Here, MTOR is linked to breast carcinoma.